Related Experiment Video

Updated: Jul 13, 2026

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved

Miguel López-Lázaro1

  • 1University of Seville, Department of Pharmacology, Faculty of Pharmacy, Sevilla, Spain. mlopezlazaro@us.es

Expert Opinion on Therapeutic Targets
|August 2, 2007
PubMed

Insights

The cardiac drug digitoxin shows promise for cancer therapy by inhibiting cancer cell growth and inducing apoptosis. Its selective targeting of malignant cells may be due to the inhibition of glycolysis, a key metabolic pathway.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cardiac drug digitoxin exhibits preclinical and clinical anticancer potential.
  • Digitoxin inhibits cancer cell growth and induces apoptosis at therapeutic concentrations.
  • The selective toxicity of digitoxin towards cancer cells remains unclear.

Purpose of the Study:

  • To analyze the anticancer mechanisms of digitoxin.
  • To propose that inhibition of glycolysis is a key mechanism for selective cancer cell targeting.
  • To discuss the clinical evaluation of digitoxin in cancer patients.

Main Methods:

  • Literature review of preclinical and clinical data on digitoxin's anticancer effects.
  • Analysis of proposed mechanisms, focusing on glycolysis inhibition.
  • Discussion of evidence for clinical trials in cancer therapy.

Main Results:

  • Digitoxin demonstrates anticancer activity by inhibiting cancer cell proliferation and inducing apoptosis.
  • Malignant cells appear more susceptible to digitoxin than non-malignant cells.
  • Inhibition of glycolysis is proposed as a primary mechanism for digitoxin's selective anticancer action.

Conclusions:

  • Digitoxin's anticancer effects are supported by accumulating data.
  • Glycolysis inhibition is a plausible mechanism for digitoxin's selective targeting of cancer cells.
  • Further investigation is warranted to determine the clinical utility of digitoxin in cancer treatment.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.